Aarti Industries Ltd · NSE:AARTIIND

Aarti Industries — Q4 FY2020 Earnings Presentation

16 slides from Aarti Industries's earnings presentation, May 26, 2020

  1. Slide 1: Exchange cover letter for results presentation

    & AARTI INDUSTRIES LIMITED Ref. No.: AIL/B-40/2020/096 May 26, 2020 To, To, Listing/Compliance Department Listing/Compliance Department BSE LTD. National Stock Exchange of Phiroze Jeejeebhoy Towers, India Limited Dalal Street, “Exchange Plaza”, Plot No. C/1, Mumbai — 400 001. G Block Bandra-Kurla Co

  2. Slide 2: Q4 & FY20 Results Presentation

    AARTI INDUSTRIES LIMITED Q4 & FY20 Results Presentation May 2020

  3. Slide 3: Disclaimer

    Disclaimer AARTI INDUSTRIES LIMITED may, from time to time, make written and oral forward looking statements, in addition to statements contained in the company's filings with BSE Limited [BSE] and National Stock Exchange of India Limited [NSE], and our reports to shareholders. The company does not

  4. Slide 4: Agenda

    Agenda 1 | At a glance 2 | Quarterly and Annual performance 3

  5. Slide 5: Company Overview

    Company Overview Overview Key Metrics  A leading Speciality Chemicals company in Benzene based derivatives with integrated operations and high level of cost optimization 200+ 400+ 700+ Global Domestic  Established by first generation technocrats in 1984 Products Customers Customers  Pharma operat

  6. Slide 6: Key Strengths

    Key Strengths • Global Player in Benzene based Derivatives with Integrated Operations o Strong/Leadership position in key products and processes o Integrated operations across product chain of Benzene and Toluene o Ability to effectively use co-products and generate value-added products • Well Diver

  7. Slide 7: Key Highlights for FY20

    Key Highlights for FY20 Major factors impacting performance ● Nitric Acid Shortage Impacting Chemical Segment Volumes (in Q2 and Q4) ● COVID-19 Lockdown Impact (end of Q4) - Logistics impacted affecting supply chain and despatch to customers, - Port movement affected impacting exports, - Restriction

  8. Slide 8: Agenda

    Agenda 1 | At a glance 2 | Quarterly & Annual performance 7

  9. Slide 9: Chairman's Message

    Chairman’s Message Commenting on the performance for Q4 and FY20, Mr. Rajendra Gogri – Chairman & MD at Aarti Industries Limited said, “FY20 saw the business impact from global economic weakness, slow demand in some large usage verticals, sharp volatility in the prices of key raw materials and curre

  10. Slide 10: Q4 & FY20 P&L (Consolidated)

    Q4 & FY20 P&L (Consolidated) Particulars Y-o-Y Y-o-Y  Revenue & EBIDTA impacted FY20 FY19 Q4 FY20 Q4 FY19 due to weakness in some (Rs. Crore) (%) (%) usage verticals, shortage of Gross Income from Operations 4,621 4,706 -1.8% 1,190 1,279 -7.0% raw material and Covid-19 related restrictions Exports

  11. Slide 11: Q4 & FY20 – Speciality Chemicals (Consolidated)

    Q4 & FY20 – Speciality Chemicals (Consolidated) Revenue Revenue 3980 3865 988 984  Higher margins on account of increasing share of value added and high margin products  Nitric Acid Shortage and Q4 FY19 Q4 FY20 FY19 FY20 Commissioning of new units impacted the EBIT. Overall impact at EBIT due to t

  12. Slide 12: Q4 & FY20 – Pharma (Consolidated)

    Q4 & FY20 – Pharma (Consolidated) Revenue Revenue  Pharma business revenue lower by 3% 726 756 YoY in Q4 and higher by 4% in FY20. 213 206  On account of COVID, revenue impacted by about 2-3%, while EBIT was impacted by about 3-5%.  The USFDA approved unit at Tarapur was inspected by the USFDA au

  13. Slide 13: Revenue Performance (Consolidated)

    Revenue Performance (Consolidated) Revenue Export Deep engagement with Operating revenues have grown on the back of global customers in CAGR: 11% 1,977 1,966 Speciality Chemicals and strong volume growth in key business segments and 1,523 1,596 Pharma. In addition, some 1,431 4,705 4,621 part of dom

  14. Slide 14: EBIT Performance (Consolidated)

    EBIT Performance (Consolidated) EBIT Higher growth relative to revenue CAGR: 15% highlights value addition 932 952 delivered by AIL 663 615 542 FY16 FY17 FY18 FY19 FY20 Speciality Chemicals Pharmacuticals CAGR: 13% 819 CAGR: 37% 137 814 113 566 581 504 79 39 48 FY16 FY17 FY18 FY19 FY20 FY16 FY17 FY1

  15. Slide 15: Contact Us

    Contact Us For further information please log on to www.aarti-industries.com or contact: Mr. Chetan Gandhi / Mr. Raj Sarraf Aarti Industries Limited Tel: +91 22 6797 6666 Email: info@aarti-industries.com Shiv Muttoo / Shruti Joshi CDR India Tel: +91 98335 57572 / +91 75065 67349 Email: shiv@cdr-indi

  16. Slide 16: Thank You

    Thank You

Aarti Industries — Q4 FY2020 Earnings Presentation on 6ix